Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ

$32.10

+0.91%
HealthcareBiotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.86B
EPS2.7600
P/E Ratio11.63
Earnings Date08/04/2026

hrmy

Operating Expenses

Last Annual Value

461.64M

3-Year CAGR

25%

5-Year CAGR

32%

10-Year CAGR

27%

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Competitors Analysis of Operating Expenses

HRMY · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
461.64M
19.8%23.2%N/A 
249.00M
25.0%24.4%15.4%
BHVN logo
Biohaven Ltd.
NYSE:BHVN
741.24M
19.3%27.6%N/A
88.33M
20.6%N/AN/A
288.90M
88.1%66.5%7.5%
165.64M
27.9%35.3%N/A
267.52M
38.9%23.4%N/A
315.47M
45.7%55.8%N/A
Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Fair Value Envelope

HRMY · NASDAQ

Our analysis suggests that HRMY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.1, this represents a potential HIDDEN relative to our calculated worth for Harmony Biosciences Holdings, Inc..

Intrinsic Value
Current Price: $32.1